What KRAS mutations, if any, would you omit when using daraxonrasib in patients with metastatic pancreatic adenocarcinoma?

There is no reason to exclude any RAS mutation or RAS wild-type tumors. All types demonstrated benefit in the RASolute 302 study, albeit in smaller numbers. All PDAC patients should be considered for daraxonrasib in the second-line setting, as it is superior to second-line chemo.